Advances in KRAS mutation inhibition in metastatic colorectal cancer

[1]  K. Takabe,et al.  Immunotherapy: Recent Advances and Its Future as a Neoadjuvant, Adjuvant, and Primary Treatment in Colorectal Cancer , 2023, Cells.

[2]  A. Addeo,et al.  Drugging KRAS: current perspectives and state-of-art review , 2022, Journal of Hematology & Oncology.

[3]  A. Koide,et al.  Inhibition of RAS-driven signaling and tumorigenesis with a pan-RAS monobody targeting the Switch I/II pocket , 2022, Proceedings of the National Academy of Sciences of the United States of America.

[4]  J. Krauss,et al.  315O Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort , 2022, Annals of Oncology.

[5]  J. Christensen,et al.  LBA24 KRYSTAL-1: Updated efficacy and safety of adagrasib (MRTX849) with or without cetuximab in patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation , 2022, Annals of Oncology.

[6]  T. Burns,et al.  OA03.06 CodeBreaK 100/101: First Report of Safety/Efficacy of Sotorasib in Combination with Pembrolizumab or Atezolizumab in Advanced KRAS p.G12C NSCLC , 2022, Journal of Thoracic Oncology.

[7]  Kwok-Kin Wong,et al.  The current state of the art and future trends in RAS-targeted cancer therapies , 2022, Nature Reviews Clinical Oncology.

[8]  M. Meyerson,et al.  Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D mutated non-small cell lung cancer. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Mallika Singh,et al.  Abstract 3597: Direct targeting of KRASG12X mutant cancers with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor , 2022, Cancer Research.

[10]  Mallika Singh,et al.  Abstract 3596: RM-036, a first-in-class, orally-bioavailable, Tri-Complex covalent KRASG12D(ON) inhibitor, drives profound anti-tumor activity in KRASG12D mutant tumor models , 2022, Cancer Research.

[11]  Mallika Singh,et al.  Abstract 3598: A first-in-class tri-complex KRASG13C(ON) inhibitor validates therapeutic targeting of KRASG13Cand drives tumor regressions in preclinical models , 2022, Cancer Research.

[12]  S. Ramalingam,et al.  Largest evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated non–small cell lung cancer (NSCLC) and colorectal cancer (CRC): Plasma biomarker analysis of CodeBreaK100. , 2022, Journal of Clinical Oncology.

[13]  K. Shokat,et al.  Drugging the Next Undruggable KRAS Allele-Gly12Asp. , 2022, Journal of medicinal chemistry.

[14]  P. Jänne,et al.  First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1) , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Zheng,et al.  Cancer incidence and mortality in China, 2016 , 2022, Journal of the National Cancer Center.

[16]  N. Kraut,et al.  Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants , 2022, Cancer discovery.

[17]  J. Parker,et al.  Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition , 2022, The Journal of clinical investigation.

[18]  J. Blake,et al.  Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor. , 2021, Journal of medicinal chemistry.

[19]  Myung Ah Lee,et al.  Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. , 2021, The Lancet. Oncology.

[20]  A. Azmi,et al.  KRAS Inhibitors- yes but what next? Direct targeting of KRAS- vaccines, adoptive T cell therapy and beyond. , 2021, Cancer treatment reviews.

[21]  J. Tabernero,et al.  P-71 KRYSTAL-10: A randomized phase 3 study of adagrasib (MRTX849) in combination with cetuximab vs chemotherapy in patients with previously treated advanced colorectal cancer with KRASG12C mutation , 2021, Annals of Oncology.

[22]  J. Soh,et al.  KRAS secondary mutations that confer acquired resistance to KRAS G12C inhibitors, sotorasib and adagrasib, and overcoming strategies: insights from the in vitro experiments. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  P. Chang,et al.  KRAS Mutation Dictates the Cancer Immune Environment in Pancreatic Ductal Adenocarcinoma and Other Adenocarcinomas , 2021, Cancers.

[24]  R. Heist,et al.  Clinical acquired resistance to KRASG12C inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation. , 2021, Cancer discovery.

[25]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[26]  Caroline H. Johnson,et al.  Immune landscape and prognostic immune-related genes in KRAS-mutant colorectal cancer patients , 2021, Journal of translational medicine.

[27]  Kwok-Kin Wong,et al.  SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling , 2020, The Journal of experimental medicine.

[28]  P. Hammerman,et al.  Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling , 2020, Clinical Cancer Research.

[29]  A. Pandiella,et al.  Proteolysis targeting chimeras (PROTACs) in cancer therapy , 2020, Journal of Experimental & Clinical Cancer Research.

[30]  P. Ettmayer,et al.  BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition. , 2020, Cancer discovery.

[31]  Guoqiang Dong,et al.  Discovery of Novel PDEδ Degraders for the Treatment of KRAS Mutant Colorectal Cancer. , 2020, Journal of medicinal chemistry.

[32]  N. Rosen,et al.  EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer. , 2020, Cancer discovery.

[33]  Yongcheng Song,et al.  Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy , 2020, Journal of Hematology & Oncology.

[34]  C. Crews,et al.  Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs , 2020, ACS central science.

[35]  D. Lambrechts,et al.  Precision therapy in RAS mutant colorectal cancer. , 2020, Gastroenterology.

[36]  Davide Risso,et al.  Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition , 2020, Nature.

[37]  J. Desai,et al.  The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity , 2019, Nature.

[38]  M. Koegl,et al.  Drugging an undruggable pocket on KRAS , 2019, Proceedings of the National Academy of Sciences.

[39]  S. Guraya.  Pattern, Stage, and Time of Recurrent Colorectal Cancer After Curative Surgery. , 2019, Clinical colorectal cancer.

[40]  H. Briem,et al.  Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction , 2019, Proceedings of the National Academy of Sciences.

[41]  J. Fernandez-Banet,et al.  The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients. , 2019, Cancer discovery.

[42]  P. Zarrinkar,et al.  Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor , 2018, Cell.

[43]  M. Zhou,et al.  Trend analysis of cancer incidence and mortality in China , 2017, Science China Life Sciences.

[44]  K. Haigis.  KRAS Alleles: The Devil Is in the Detail. , 2017, Trends in cancer.

[45]  J. Gartner,et al.  T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. , 2016, The New England journal of medicine.

[46]  V. Heinemann,et al.  Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  Jurgen Müller,et al.  Negative feedback regulation of the ERK1/2 MAPK pathway , 2016, Cellular and Molecular Life Sciences.

[48]  Yi Liu,et al.  Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State. , 2016, Cancer discovery.

[49]  Neal Rosen,et al.  Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism , 2016, Science.

[50]  S. Fesik,et al.  Drugging the undruggable RAS: Mission Possible? , 2014, Nature Reviews Drug Discovery.

[51]  Kevan M. Shokat,et al.  K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions , 2013, Nature.

[52]  R. Auer,et al.  Surveillance after Curative Resection of Colorectal Cancer , 2009, Clinics in colon and rectal surgery.

[53]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[54]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..